Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Primer on Copay Accumulator Programs

Donald Miller, PharmD, & Laura Sampson, PA-C  |  Issue: August 2022  |  June 17, 2022

After two years of virtual meetings, the Advocacy Leadership Conference was once again held in person in Washington, D.C., May 11–13. The conference educates ACR/ARP volunteer leaders about topics important to rheumatologists, rheumatology professionals and their patients that they can then discuss with their members of Congress and staff. One important issue ACR volunteers discussed with their representatives and senators this year was the growing use of copay accumulator programs, which restrict the application of patient assistance funds toward patient cost-sharing requirements.

Dr. Miller

Patient assistance programs provided by pharmaceutical companies make expensive medications more affordable to the patient by funding part of the cost. Manufacturers fund these programs to reduce financial barriers to prescription of their drugs and ensure a profitable net return to the company. The practice has been compared to a form of bribery. That is why insurance companies have concerns about these programs, and management of them has important policy implications.

Ms. Sampson

Let’s say an individual is offered either methotrexate or adalimumab for their rheumatoid arthritis (RA). Normally, a high co-pay on the adalimumab would discourage many patients from taking it. But if AbbVie covers most of the copay, the patient will frequently choose the more expensive drug.

In response, most commercial insurance carriers no longer apply patient assistance program contributions toward patients’ deductibles or out-of-pocket maximums. These copay accumulator programs essentially require a patient pay twice for drug costs: once with an assistance program and again with their own money. This creates an additional financial barrier to treatment for the patient.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Lack of Transparency

A rule from the Centers for Medicare & Medicaid Services finalized in July 2020 allows commercial insurers to use copay accumulators even if a brand name drug has no generic equivalent or appropriate alternative. There is no requirement for transparency from insurers about these programs, often resulting in big surprises for patients.

Many manufacturer copay assistance programs fund a treatment for only one year; after the assistance runs out, patients often cannot afford to pay for the prescription. Patients often don’t even know about these policies until the coupons are no longer usable, and the impact is devastating—often, discontinuation of the drug.

Tami Byklum of North Dakota has a daughter with juvenile arthritis who has been on biologics all through her arthritis journey. Her husband has RA and is on an expensive biologic as well. Her family has a steep deductible before insurance pays 100% of covered services, and they have relied on copay assistance programs to help afford their treatments. Ms. Byklum’s employer changed insurance companies in January 2022, and she was informed the company would no longer recognize third-party payers and copay programs as payment toward their deductible. This meant the family needed to come up with $7,000 at the beginning of the year, and they were in a panic. 

Page: 1 2 3 | Single Page
Share: 

Filed under:Interprofessional PerspectiveLegislation & Advocacy Tagged with:Access to careAdvocacy Leadership Conferencecopay accumulatorsdrug costsLegislation & Advocacy

Related Articles
    felipe caparros / shutterstock.com

    Copay Accumulator Programs Can Derail Rheumatologic Treatment Plans

    February 13, 2020

    As the medications for rheumatology become more expensive, the need for patient financial assistance becomes paramount. Unfortunately, commercially insured patients are finding it difficult to afford the exorbitant copays required by their plans, and the latest strategy of pharmacy benefit managers (PBMs) threatens to derail rheumatologic treatment goals. High deductible plans combined with copay accumulator…

    Copay Accumulator & Maximizer Programs Threaten Access to Treatment

    July 6, 2023

    As health insurance companies and third-party benefit managers continue to use copay accumulators and maximizers to shift the cost of specialty drugs to patients, the ACR continues to advocate against programs that limit copay assistance.

    Rheumatologists Concerned High Healthcare Costs May Encourage Patients to Forgo, Delay Treatment

    June 14, 2017

    While members of Congress debate healthcare legislation, rheumatologists say many of their patients struggle to afford everything from generic drugs to insurance copayments for physical therapy. “It’s a mess. The cost of prescriptions and the rationale for those rising costs in the U.S. right now—it’s just a mess,” says James R. O’Dell, MD, Stokes-Shackleford Professor of…

    ACR Leads Resolution to Address Copay Accumulator Policies at AMA House of Delegates Meeting

    November 6, 2020

    If passed, the ACR-authored resolution will direct the AMA to advocate for copay accumulator bans at state and federal levels. Several other specialties and state medical associations have joined the resolution as cosponsors.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences